Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.

British journal of haematology - 1 Oct 2014

Meja Koremu, Stengel Chloe, Sellar Rob, Huszar Dennis, Davies Barry R, Gale Rosemary E, Linch David C, Khwaja Asim

Abstract excerpt

PIM kinases (PIM1, 2 and 3) are involved in cell proliferation and survival signalling and are emerging targets for the therapy of various malignancies. We found that a significant proportion of primary acute myeloid leukaemia (AML) samples showed PIM1 and PIM2 expression by quantitative reverse transcription polymerase chain reaction. Therefore, we investigated the effects of a novel ATP-competitive pan-PIM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Leukemia, Myeloid, Acute

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 24975213
DOI: 10.1111/bjh.13013

Genes

MCL1
PIM1
FLT3
PIM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.PMID 24975213Read ↗

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.Semantic proximity Read ↗

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read ↗

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.Semantic proximity Read ↗

The PIM kinases in hematological cancersSemantic proximity Read ↗

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.Semantic proximity Read ↗

Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist VenetoclaxSemantic proximity Read ↗

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.Semantic proximity Read ↗

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read ↗

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.Semantic proximity Read ↗

Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.Semantic proximity Read ↗

PIM1 kinase as a target for cancer therapySemantic proximity Read ↗

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.